Ropinirole
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
- Ropinirole
- Ropinirole: From Parkinson’s Disease/Restless Legs Syndrome to Attention-Deficit/Hyperactivity Disorder
Ropinirole: From Parkinson’s Disease/Restless Legs Syndrome to Attention-Deficit/Hyperactivity Disorder
One-Sentence Summary
Ropinirole is a non-ergot dopamine D2/D3 receptor agonist, historically associated with Parkinson’s disease and restless legs syndrome (RLS) management based on the supporting literature in this evidence pack. The TxGNN model predicts it may be effective for Attention-Deficit/Hyperactivity Disorder (ADHD), but this is currently supported only by 0 clinical trials and 8 publications, none of which are randomized controlled trials directly testing ropinirole in ADHD.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available from registry data (drug is not marketed in India, total_licenses = 0). Literature context in this pack references ropinirole’s established use in Parkinson’s disease and restless legs syndrome. |
| Predicted New Indication | Attention-Deficit/Hyperactivity Disorder (ADHD) |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L4 |
| India Market Status | ✗ Not Marketed (Not marketed) |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (flagged as a High-severity data gap, DG002). Based on the pharmacology referenced in the supporting literature, ropinirole is a non-ergot dopamine D2/D3 receptor agonist, a class conventionally used for Parkinson’s disease and RLS.
The link to ADHD is indirect rather than a direct pharmacological rationale. Most of the supporting literature discusses the comorbidity between RLS and ADHD rather than ropinirole’s action on ADHD’s core neurobiology. Only one publication (PMID 15866437) describes a pediatric case in which ropinirole — prescribed to treat RLS/periodic limb movement symptoms in a child who already had ADHD — coincided with improvement in both sleep and ADHD symptoms. This is a single case report, not a controlled study of ropinirole as an ADHD therapy.
Mechanistically, dopaminergic dysregulation is implicated in ADHD pathophysiology (most ADHD drugs, e.g., methylphenidate, act on dopamine/norepinephrine reuptake), so a dopamine agonist is biologically plausible as a candidate. However, the current evidence base does not distinguish whether any benefit is via direct ADHD-relevant circuitry or secondary to RLS symptom relief improving sleep and attention. The mechanistic link should be considered weak and hypothesis-generating only.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 16218085 | 2005 | Review | Sleep | Reviews the RLS–ADHD association, hypothetical shared mechanisms, and rationale for shared pharmacologic treatment when co-occurring. |
| 18656214 | 2008 | Review | Revue neurologique | General review of RLS pathophysiology and diagnostic criteria; does not directly address ADHD treatment. |
| 15866437 | 2005 | Case Report | Pediatric neurology | 6-year-old with ADHD and comorbid RLS/PLMS treated with ropinirole (for RLS) showed improvement in both RLS symptoms and ADHD symptoms. |
| 30950895 | 2019 | Case Report (unrelated) | Cornea | Describes corneal edema in patients exposed to systemic dopaminergic agents; unrelated to ADHD. |
| 30460371 | 2019 | Case Report (unrelated) | Acta dermato-venereologica | Treatment-induced delusions of infestation linked to elevated brain dopamine; unrelated to ADHD. |
| 24992083 | 2014 | Cohort (unrelated drug) | Clinical neuropharmacology | Compares piribedil vs. pramipexole/ropinirole on vigilance in Parkinson’s disease patients with daytime sleepiness; not ADHD-related. |
| 17483695 | 2007 | Preclinical (animal model) | J Neuropathol Exp Neurol | A11-lesioned, iron-deprived mouse model proposed as an RLS model; does not test ropinirole or ADHD endpoints. |
| 34182128 | 2021 | Basic Science | Pharmacological research | Receptor heteromerization study (α2A adrenoceptor/dopamine D4 variants) relevant to ADHD/impulse-control biology, but not a ropinirole efficacy study. |
India Market Information
Currently no registration records available in India — the drug is recorded as Not Marketed (total_licenses = 0), so no authorization/product/dosage-form entries exist in this evidence pack.
Safety Considerations
Drug Interactions: DDI screening identified 167 total interactions. The interactions flagged at Moderate severity include:
- Morphine
- Morphine (liposomal)
- Cimetidine
- Dronabinol
- Nabilone
- Opium
- Obeticholic acid
- Metoclopramide
The remaining flagged interactions (e.g., Calcitriol, Phentermine, Pantoprazole, Glimepiride, Mesalazine, Doxycycline, Clotrimazole, Acarbose, Sucralfate, Palonosetron, Rosiglitazone, Lactulose) are recorded at Unknown severity level in the source database and require independent verification before clinical use.
Key warnings and contraindications from the local regulatory label are not currently available (Blocking data gap, DG001 — TFDA/India label PDF not yet retrieved and parsed).
Conclusion and Next Steps
Decision: Hold
Rationale: The ADHD signal rests on TxGNN’s prediction score alone plus a single pediatric case report where ropinirole treated comorbid RLS rather than ADHD directly; there is no clinical trial evidence, and the drug currently has no market presence or registered license in India. This does not meet the bar to proceed even with guardrails.
To proceed, the following is needed:
- Resolve Blocking gap DG001: obtain and parse the official label (TFDA or equivalent) for warnings/contraindications — this is required before any S1 safety screening.
- Resolve High-severity gap DG002: confirm ropinirole’s formal MOA (D2/D3 agonism) via DrugBank API to support mechanistic review.
- Seek prospective or controlled studies testing ropinirole specifically for ADHD (not RLS-ADHD comorbidity) before advancing past S0.
- Note: within this same evidence pack, the schizophrenia candidate (rank 5) has a stronger evidence base (L3, decision_stage S1, “Research Question,” including a systematic review/meta-analysis, PMID 31688399) and may warrant separate evaluation as a higher-priority research question relative to the ADHD signal.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.